Substance P Antagonists dosing & administration
NK1 receptor blockers that reduce pain signals and nausea at the source
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
150 mg (fosaprepitant)
Frequency
Single dose, 30 min before chemotherapy on day 1
Duration
One dose per chemotherapy cycle
FDA-approved single-dose IV prodrug regimen, with a 5-HT3 antagonist and corticosteroid [5].
Timing
Best time to take
Take Substance P Antagonists at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Substance P Antagonists can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Substance P Antagonists should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Substance P Antagonists is administered Oral capsule—no injection required
Best sites
Storage
Before reconstitution
Store Substance P Antagonists in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Substance P Antagonists should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Oral capsule—rotate sites if applicable
Maintain a consistent schedule for optimal results with Substance P Antagonists. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Headache, Fatigue or weakness, Constipation
Less common: Loss of appetite, Dizziness
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Substance P Antagonists
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Substance P Antagonists should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Strong CYP3A4 inhibitors (like ketoconazole, ritonavir) - risk of increased aprepitant levels — Use with caution—discuss with your healthcare provider.
- Pimozide - risk of serious arrhythmias — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Han DS, et al. · 2023
Substance P and ASIC3 channels mediated pain in fibromyalgia models, with antagonists abolishing pain responses. NK1 receptor blockade reduced mechanical hyperalgesia through ASIC3-containing channels in muscle afferents.
Velasco-Ortega E, et al. · 2020
Substance P antagonists effectively reduced oral pain and inflammation through NK1 receptor blockade. The system plays a critical role in chemotherapy-induced mucositis and inflammatory pain conditions.
Hong X, et al. · 2024
NK1 antagonists demonstrated therapeutic potential across multiple indications including nausea, pain, depression, and anxiety. Beyond chemotherapy-induced nausea, these antagonists show promise for psychiatric and neurological conditions.
Song X, et al. · 2025
Substance P released from trigeminal nerves drives neurogenic inflammation through CGRP, SP, and PACAP pathways. Antagonists like aprepitant show therapeutic potential for migraine management through blocking these inflammatory mediators.
Merck & Co. / U.S. FDA · 2010
Head to head
Substance P Antagonists compared
Studied for
Conditions Substance P Antagonists has been researched in
Want the full picture?
The complete Substance P Antagonists research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.